
Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma
The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.
Sanofi announced on Sept. 28, 2020 that it has completed its acquisition of Principia Biopharma, a late-stage biopharmaceutical company located in San Francisco, CA, for approximately $3.68 billion.
The acquisition, first announced in
Sanofi and Principia had previously formed a collaboration in 2017 under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.